Background—Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …

Transthyretin (ATTR) cardiac amyloidosis may be because of mutant transthyretin causing
familial amyloid cardiomyopathy (FAC) or wild-type transthyretin causing systemic senile …

Purpose Cardiac transthyretin-related amyloidosis (ATTR) is a progressive and fatal
cardiomyopathy. The diagnosis of this disease is frequently delayed or missed due to the …

Technetium-labeled cardiac scintigraphy (ie, Tc-PYP scan) has been repurposed for the
diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). Validated in cohorts of …

Background—Differentiating immunoglobulin light-chain (AL) from transthyretin-related
cardiac amyloidoses (ATTR) is imperative given implications for prognosis, therapy, and …

Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy
caused by extracellular deposition of transthyretin, normally involved in the transportation of …

Cardiac amyloidosis, once considered untreatable, is now gaining well-deserved attention
due to advances in imaging and the recent approval of targeted breakthrough therapies. In …

Background: Amyloidosis is characterized by extracellular deposits of insoluble proteins that
cause tissue damage. The three main types are monoclonal light chain (AL), wild-type …

Objectives This study aimed to characterize trends in technetium Tc 99m pyrophosphate
(99mTc-PYP) scanning for amyloid transthyretin cardiac amyloidosis (ATTR-CA) diagnosis …

Background: Cardiac transthyretin amyloidosis (ATTR) is an increasingly recognized cause
of heart failure. Cardiac magnetic resonance (CMR), with late gadolinium enhancement …